For the second day in a row, Katherine, a trade representative to the United States, heard criticism from Republican lawmakers that the intellectual property rights waiver would give China, Russia and other strategic rivals critical biopharmaceutical technology while failing to increase vaccine supply.
Catherine So, the US trade representative, said on Thursday that the waiver of intellectual property for the World Trade Organization (WTO) COVID-19 vaccine was an opportunity for deeply divided trade bodies to align themselves with the needs of the world.
So, speaking to the House Way and Mines Committee, he said he was committed to taking part in discussions that would address the concerns of all parties, including pharmaceutical companies.
“The WTO has no record of taking swift action or getting a yes, about 1 agree4 members must all agree, they often agree,” he said. “This is an opportunity for the WTO to show its relevance to the human race.”
For the second day in a row, Taiwan heard criticism from Republican lawmakers that the intellectual property rights waiver would provide critical biopharmaceutical technology to China, Russia and other strategic rivals, as well as failing to increase vaccine supply.
Republican Rep. Devin Nunes told Tai that he is concerned that some countries could quickly develop Messenger RNA vaccines, a technology that is partially developed with U.S. tax dollars.
“It simply came to our notice then [China] They want to steal this very new technology, especially those related to Modarna and Pfizer vaccines. “
So he said the administration is trying to practice leadership on this issue in order to save lives and bring the world back on the path of rapid development that will benefit America.
Therefore, he said, India and South Africa, proponents of the original and much broader proposal, are expressing that they feel extremely weak because they do not have access to vaccines and are unable to develop them.
At a Senate hearing Wednesday, he said vaccine companies could be “heroes” in helping the world increase access to the COVID-19 vaccine.
He declined to discuss details of his consultations with pharmaceutical companies before announcing his decision to join the WTO waiver talks last week, but said some partners have been driven beyond their obligations.
“Some of them see themselves as important actors in the world’s public health ecosystem,” he said.
That is why it was said that waiving intellectual property was the only way to increase the production and fair distribution of vaccines worldwide.